Kamada Ltd. (TLV:KMDA)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
2,650.00
+27.00 (1.03%)
Nov 16, 2026, 5:26 PM IST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 10, 2026

Summary

First-nine-month results showed growth across financial metrics, with strong cash generation and dividends. Growth plans include biosimilar launches, plasma sales and a potential acquisition, while margin gains are supported by scale and in-house manufacturing.

Annabel Samimy
Analyst, Stifel

All right, we're going to get started here. Good morning, everyone, and welcome to the Kamada session.

Amir London
CEO, Kamada

Special session.

Annabel Samimy
Analyst, Stifel

Special session. Kamada is a developer, a specialty plasma. Oh my God, this is a mess. Specialty plasma company, diversified global specialty plasma company. Here with us to talk about it is Amir London, who is CEO of Kamada. Amir, welcome, and why don't I give you the floor and have you give an overview of Kamada and your unique place in this market?

Amir London
CEO, Kamada

Perfect. Thanks, Annabel, and thank you , everyone, for joining. Can you hear me well? Yes? Okay. Like Annabel said, Kamada is a specialty pharma, specialty plasma, global company, dual traded Tel Aviv and NASDAQ. We have six FDA-approved products. Over the last few years, we've grown significantly, double-digit every year, top line and bottom line. We've expanded significantly our portfolio, and we have what we call the four pillars of growth. Organic growth coming from our six FDA-approved products in a very unique niche of specialty immunoglobulin, specialty plasma products. We have what we call the in-licensing of the distribution business, where we operate in Israel and the Middle East, and we license products from third parties, international companies, and we basically provide them with a turnkey solution in those territories.

Main focus over the last two years, and that will be our main growth engine in that area, are biosimilars. We have signed multiple agreements with different companies to represent them in the region, and we just launched two additional products in that space. Thirdly, we opened, over the last few years, plasma collection centers. We use a specialty plasma for our own needs, but we also collect normal source plasma, and we recently signed a $50 million agreement to be selling that normal source plasma to an external client. Lastly, we are very active in terms of looking to grow also inorganically, through M&A and acquisition in the areas where we operate. We are searching for the right assets. We are looking for commercial assets. We would like to grow with very little risk in the way we are growing the business.

I like to say that Kamada currently has no binary events. Unlike many other biopharmaceutical companies, we are really focused on commercialization, distribution, and profitability. We had our earning call yesterday for the first nine months of the year, and I will leave it to you to ask me about it.

Annabel Samimy
Analyst, Stifel

Okay. Well, tell us about your third quarter earnings call.

Amir London
CEO, Kamada

Yeah

Annabel Samimy
Analyst, Stifel

And-

Amir London
CEO, Kamada

Yeah, so we had the.

Annabel Samimy
Analyst, Stifel

How is the performance going?

Amir London
CEO, Kamada

Yeah. We had a very strong first nine months. This has been growing in all financial metrics, top line, bottom line, gross margins, and cash. Last year, we basically started also paying dividends to our shareholders. That will be the third time this year we will be paying dividend. If you look at our EBITDA and cash generation, around $37 million of cash generated first nine months of the year, EBITDA of over $40 million, and a dividend of around $32 million paid back to our shareholders. All of that with a strong cash position, around $75 million. We do not need to go back to the market anytime soon in order to raise funds. We have sufficient resources also to execute the different executions or different acquisitions that we would like to do. It is a very solid financial situation.

Annabel Samimy
Analyst, Stifel

Okay. Maybe we can just step back a little bit for people who are not as familiar with the specialty plasma market. Can you talk about that market?

Amir London
CEO, Kamada

Yeah.

Annabel Samimy
Analyst, Stifel

It is relatively well protected. It has got some high barriers to entry. Can you sort of describe that market and—

Amir London
CEO, Kamada

Yeah. In general, I think most of the plasma industry is around what's called IVIG and albumin. There are a few giants in that market, Grifols, CSL, Takeda. We have decided, basically almost from day one at Kamada, that we will be focusing on the specialty side of the plasma business. These are not commodity IVIG but specialty immunoglobulins. The entry barrier is very high, and we are not finding new companies developing products in that space. The ability to collect a high-titer, high-potency plasma is complicated. It requires unique expertise to identify those, what we call the super donors, the one that have high titer, and then to bring them back into our centers and over and over again in order to donate plasma. The ability to quantify, and simplifying it a little bit, to quantify the plasma titer is also complicated.

You need to have special testing, what's called neutralization testing, to identify those specific donors. The fact that there is complexities and limitations around the plasma sourcing, you don't just pick up the phone, call a supplier somewhere, and order this raw material. This is a very unique, hard-to-make type of raw material, and we know how to do it. This is kind of the entry into that space. Adding to that is the only less than 10 companies worldwide that have an FDA-approved plasma products. That's all. So they have a high standard of manufacturing, regulatory compliance, quality GMP, and we know how to do it. We've been doing it for over 30 years, and over the last few years, we really found our kind of specialty niche in making those products.

Every product that we have, we have maybe one to two competitors max. Our lead product is anti-rabies immunoglobulin for people that were exposed to potentially rabid animals. There's only two products of that type in the U.S., FDA approved, us and our competitor, and we are now over 50% market share. We believe we're over 50% market share. CYTOGAM, it's an anti-CMV product used as part of transplantation, the only product of its kind. VARIZIG, anti-varicella zoster for immunocompromised populations that have been exposed to chickenpox. I almost said "exposed to potentially rabid animal," but that's from a different story. Exposed to chickenpox, and that, again, the only product of its kind in the U.S. approved by the FDA. So these are really unique niche types of products, and we're doing well in growing them and creating awareness about the products.

We have our own commercial team that is promoting and selling the products in the U.S. We have expanded way beyond the U.S. We're now active in over 40 countries. In some of them, we work direct with our own commercial team, and some we work through a network of distributors that have this unique expertise.

Annabel Samimy
Analyst, Stifel

Great. Your portfolio is obviously very diversified. What would you say the key growth drivers are at this stage?

Amir London
CEO, Kamada

Yeah.

Annabel Samimy
Analyst, Stifel

Does that change throughout the year? Does that change from year to year? Talk to us about those dynamics.

Amir London
CEO, Kamada

Over the last two, three years, KEDRAB, this anti-rabies immunoglobulin, in the U.S. has been our number one product. Around one-third of the business right now is what we call the anti-rabies franchise, because it's not only KEDRAB in the U.S. We also have a brand called KAMRAB, which is for all ex-U.S. territories, especially LATAM, some CIS countries, Canada, Australia, Israel. This is how we sell the product in some European countries. That has been the number one product, but as you said, highly diverse. We are not relying now on one product or one territory. VARIZIG has been growing nicely. GLASSIA, after a dip that we had when the royalties from Takeda have declined, we are starting to climb again.

This year is the first year with the lower royalties, and from that point on, this will continue to grow because there's better awareness for alpha-1 deficiency, better diagnostics, and we have a very good product, which is commercial in the U.S. and Canada by Takeda. Ex-North America, we sell through a network of distributors. The distribution business is also growing. We had a very nice growth basically in the first three quarters of the year. We sold exactly like we sold for the entire year last year in 2025, the distribution product. We've made the decision a few years ago to focus. When I say distribution, it's an in-licensing product that we sell in the Middle East and Israel, where we have our own commercial infrastructure. Of that, we decided to focus within that space on the biosimilars.

We have signed numerous agreements by now. I think we have like six or seven different agreements with different international biosimilar companies, and we started launching the products. We have four products now launched in Israel, two more to be launched next year. We guided the market that by 2028, we expect already $10 million of sales, growing to around $25 million by 2030. That is kind of nice wave of the biosimilar trend that we have been riding, and that will be another growth engine of our business. We are just now basically kind of in December; we will be starting to sell for the first time plasma to an external client. That will be, again, another growth engine of the next few years.

We have a $50 million agreement, meaning that next year will be around $16 million-$17 million, that this year is only like $3 million or $4 million. So another like $10 million plus growth will be coming from the plasma sales.

Annabel Samimy
Analyst, Stifel

Okay, great. That is a lot, so I am going to break them down a little bit. First on the actual specialty products for KEDRAB. What has been the growth driver there in terms of rabies prophylaxis?

Amir London
CEO, Kamada

Yeah. I think it is combined of two aspects. One, we have been taking greater market share. We have highly competitive product. Of the two products in the U.S., we are the only one that did also a pediatric study, and we have on label that the product has been tested positively on children. I think that is a nice competitive edge compared to the competition. Secondly, we are working with a very strong partner in the U.S. market in the plasma space, Kedrion. They have done very well in recent years in growing their portfolio through acquisitions and licensing, and I think they have a very nice kind of capabilities to promote the product in the market.

Every hospital in America needs to have an anti-rabies product on their shelf, because at any given moment, someone may step in basically being exposed to a bat or to a raccoon or to a fox or an unvaccinated domestic animal, and that's a real life-threatening situation. Rabies is, if you're not treated and you've been exposed to a rabid animal, this is 100% death. On the other hand, if you are treated, this is 100% preventable. Doctors don't take the risk and supposed to treat. I think that the fact that there's been very active work in the field by both parties, us and the competitor, improved the awareness.

People that in the past maybe did not get the full protocol now getting the full protocol. The whole market has increased, and we've been taking significant market share from the competitor.

Annabel Samimy
Analyst, Stifel

How much did the CDC report help with that? Can you maybe describe that?

Amir London
CEO, Kamada

The CDC report that came out a few weeks ago basically spoke about the fact that there is a significant increase in number of cases in the U.S. and usage of anti-rabies vaccines and immunoglobulins. I'm not sure it helped in terms of creating more cases, of course. I think it helped by another level of awareness, and we came out immediately after that with basically a public announcement that we have the capacity and the inventory to continue supporting the market and that we are seeing that growth, and we are part of it, and we are here basically to continue protecting the people in America that require this type of treatment. Yes.

Annabel Samimy
Analyst, Stifel

Okay. Just moving to VARIZIG next.

Amir London
CEO, Kamada

Yep. VARIZIG is a very nice

Annabel Samimy
Analyst, Stifel

That's been a big growth driver.

Amir London
CEO, Kamada

VARIZIG, very nice product because again, it's very unique. It's part of the protocol. This is for immunocompromised population, could be premature babies, could be pregnant women, could be patients that are being treated for oncology patients, or patients that are with primary immune deficiency. If they are exposed to chickenpox, they need to get VARIZIG as PEP, post-exposure prophylaxis. Because of the decline in rate of vaccination in America that you're all aware of, there are less kids getting vaccinated for chickenpox, meaning there are more kids that are infected with chickenpox, which means there are more people that require to get VARIZIG as if they are being exposed. So, it is a product which is growing. We also won a very large tender by the PAHO, Pan American Health Organization, and we are their main supplier. By the way, also for rabies.

So that's another kind of territory where we have strong relationship with the health authorities, either direct or through PAHO, and we are their main supplier for those unique life-saving therapeutics. Yeah.

Annabel Samimy
Analyst, Stifel

And maybe we can talk about the clinical investment you've made in CYTOGAM and how that might be having an impact on the growth there or the utilization.

Amir London
CEO, Kamada

Yeah. So we are making a significant investment into CYTOGAM. CYTOGAM is an anti-CMV immunoglobulin product. We acquired it back in 2022. It's relatively old product that had limited clinical data, and that's for a transplant patient that are being immunosuppressed, and then they have the risk of being infected by CMV, and that's the number one reason for organ rejection. So it's very important to treat those patients, those transplant patients prophylactically, primarily as part of the transplantation itself, in order to try to prevent a CMV infection. But as I said, there was limited data supporting it. It's a pretty heavy-duty medical sale that requires to bring a lot of data. So we decided to invest in post-marketing studies.

We're working with an array of different KOLs across multiple organizations in the U.S. to either collect, analyze, and present data that they have from them treating their patients with CYTOGAM, or just proactively doing post-marketing studies. The key study, it's called SHIELD. It's led by a doctor from Mass General, Dr. Camille Kotton. She's one of the leading KOLs in America for CMV management. And what she found out that, what she called late CMV. Late CMV happens when the physicians start to trim down the use of antivirals with the patients, and it could be six months, nine months after transplantation. At that point, they see a flare of CMV infection. So the study currently is treating prophylactically with CYTOGAM those populations in conjunction with trimming down the antiviral usage. And this is for kidney transplanted patient.

That is important because right now, our main CYTOGAM use is in lung. Lungs are only like 3,000 transplant per year in the U.S., but kidney, they are around 27,000. Nine times more the prevalence, potential usage of CYTOGAM if the current study will be successful and show the data that you would like to see, and that data is supposed to be available in 2028.

Annabel Samimy
Analyst, Stifel

What is the rate of flare after they start weaning from the antivirals for kidney?

Amir London
CEO, Kamada

I like to say 25%, but I am not sure about the number. I need to double-check it. Anywhere between 25%-50%.

Annabel Samimy
Analyst, Stifel

Great. Maybe we can talk a little bit about your global expansion. That has been a big part of the growth story.

Amir London
CEO, Kamada

Yeah.

Annabel Samimy
Analyst, Stifel

What are the regions, and how has your reach been so expansive? What's your infrastructure in those regions?

Amir London
CEO, Kamada

Yeah. We have our own commercial teams in the U.S.

We are selling direct in Canada. In Canada, all plasma and blood products are being basically purchased by centralized agency, the Canadian Blood Services or Héma-Québec. We work there direct with them, and we've won the tender for all six products. We have our own commercial team in Israel and the MENA region from an office in Dubai. This is where we have basically boots on the ground, our people doing the actual commercial work. In other parts of the world, LATAM, CIS countries, Asia, some European countries, we are working with distributors and partners. Some of them we've been working together for many years, some are new, and we're in the process of identifying additional territories and countries where we can register our products. If I take GLASSIA as an example. GLASSIA is the alpha-1 antitrypsin product for people suffering from genetic disorder called alpha-1 deficiency.

This type of genetic disorder manifests as COPD-like symptoms, and we have a ready-to-use alpha-1 product given as augmentation treatment for those patients. We are going into markets where the market potential is relatively small, too small for the big companies that we compete with, which are Grifols, CSL, Takeda. They will not go into a market where there is $500,000 to $1 million opportunity. We are not shy even from that amount.

We are registering GLASSIA throughout all of LATAM, for example, as part of it. We are gaining a lot of leadership position in LATAM, and we are diagnosing with our partners new patients, identifying them, putting them on treatment. We have good capabilities in market access, and we have been doing this for now for 20 something years, so I think we are pretty good in knowing how to do it, and that is another growth engine for Kamada.

Annabel Samimy
Analyst, Stifel

Great. I want to talk about your distribution. You invested plasma collection is within the distribution business, I believe. And you have been investing a lot in this infrastructure. So how has that helped you? How much more are you going to be expanding? I think you have three plants right now.

Amir London
CEO, Kamada

Right. Three, yes.

Annabel Samimy
Analyst, Stifel

That are approved, and what are your intentions going forward?

Amir London
CEO, Kamada

In 2021, we acquired a small plasma collection center based in Beaumont, Texas. That center specialized in specialty plasma. They did not collect any normal source plasma. That was our way in into that industry, which is very unique industry in its complexities. Highly regulated. You deal with donors, people, so it is almost like a service type of industry. You need to treat them well, and you need to make sure they will repeat, come back to your center. A lot of regulatory and medical management around the donors. Once plasma is collected, it becomes your raw material. It has to be frozen. It has to be tested. There are multiple types of tests, so FDA really makes sure there is very safety guarantee of plasma, making sure there is no viral type of risk by using that plasma.

Through that acquisition, we learned that space, and then we invested and opened two additional centers, one in Houston, one in San Antonio, and those are large, really state-of-the-art centers with the capacity to collect at least 50,000 liters per year. Just imagine that is a huge space with like 50 donor beds and like 50 people staff. Not per shift, total. Those centers have been fully operational, not fully ramped up yet, but fully operational, FDA approved and EMA approved.

We use those centers to collect normal source plasma, and the normal source plasma is the base because from that point, we can either screen for specialty plasma, identify the donors that have high titer against CMV, for example, because they have naturally been exposed to CMV and developed those antibodies, or we offer those donors to join our vaccination programs like the rabies.

The specialty plasma we will be using as part of our own production. The cost of collecting a liter of plasma for us is much lower than the cost of buying a liter of plasma. Once this will become significant part of our raw material, this will have another contribution to our cost of goods. We expect this to contribute in a few points in our gross margins. The normal source plasma, which we do not need, it is like a side product for us in terms of the collection. We signed an agreement with one of the big fractionators, and we are starting now to sell them all the plasmas that we do not need.

The combination of those two together makes a center profitable, and also the importance of vertical integration because it allows us to be much more independent in the way that we manufacture, develop new specialty plasma products.

Annabel Samimy
Analyst, Stifel

Okay, great. Just to be clear, the vertical integration on the specialty plasma has not yet been incorporated.

Amir London
CEO, Kamada

Into our P&L.

Annabel Samimy
Analyst, Stifel

Into your margins. Your margins have been expanding very well, though.

Amir London
CEO, Kamada

Yes.

Annabel Samimy
Analyst, Stifel

Maybe you can talk about that margin expansion, both cost of goods or gross margins as well as EBITDA margins. They have been expanding much more beyond where you expected them to, or guided to.

Amir London
CEO, Kamada

No, we expected to.

Annabel Samimy
Analyst, Stifel

I think so.

Amir London
CEO, Kamada

Yes. I think we are enjoying benefiting from economy of scales. The fact that our plant is operating at high utilization mean that the cost per vial, cost per batch is lower because the fixed costs are being spread over greater volume of production, and that is something which is still happening. We still have room to grow in terms of bringing in more business, and the plant will be at higher utilization. I mentioned it on the rabies, but this is also true for CYTOGAM and GLASSIA. We are still making three of our products with an external manufacturer.

That was part of an acquisition we made in 2022, and we are in the process of moving those three products also to our plant. This is something we expect to complete over the next few years, and that will be another significant kind of improvement, enhancement to our gross margin because of two. For one, we are cutting the margins of the manufacturer. Secondly, we are going to improve the utilization of the plant, which means that the existing product that we make will benefit from that even further. That is another way to improve. What currently things, we are seeing the economy of scale, but also you are seeing a better kind of, let us say, weight or the way that we sell more in the U.S., we sell more in Canada. We are selling less in countries where prices have been lower.

This, of course, helps with our gross margin and with our profitability. In general, we do not need to grow our sales and marketing G&A the same rate that we are growing our top line. More cents per dollar are being translated all the way to the bottom line, and we are running now at over 25% EBITDA from top line. Last quarter was around 29%, I believe. That is, I think, the best we had, and that is just the beginning. We can continue growing this even above 30% per rate of EBITDA from top line.

Annabel Samimy
Analyst, Stifel

Great. You touched on this briefly earlier, but the biosimilar business, that is something that has just started. You started with two products, you have two more this year, and you have a few more in the next few years. How is that going to impact margins?

Amir London
CEO, Kamada

The gross margin distribution business traditionally has been low, around 15%. The new products are coming in with a gross margin of at least 30% each, 30%-40%. So over time, when this segment within our distribution business will take a bigger portion, that is going to pull our gross margin up, and we would like to be definitely above 20%, maybe up to 25% gross margin of top line. Again, economy of scale. The more products leveraging the same existing sales force, it just makes it more profitable for us. We are seeing it over the last few quarters.

Annabel Samimy
Analyst, Stifel

How should we think about the ramp of each of the new products that come in?

Amir London
CEO, Kamada

Yes. So, we guided the market, we said that we will be seeing around $25 million sales in 2030. On average, each one of those products will contribute between $1 million to $3 million to $4 million per product. And we are expecting to have eight, nine, 10 different products in the market. This is how it accumulate to the $25 million at least over the next few years. Yes.

Annabel Samimy
Analyst, Stifel

But biosimilar distribution is primarily in Israel and the MENA region.

Amir London
CEO, Kamada

Yes.

Annabel Samimy
Analyst, Stifel

I know that the dynamic of biosimilar distribution in the U.S. has been very different than what would have been expected.

Amir London
CEO, Kamada

Correct.

Annabel Samimy
Analyst, Stifel

Is that, would you say the dynamics outside of the U.S. are different?

Amir London
CEO, Kamada

Yes. No, same.

Annabel Samimy
Analyst, Stifel

No, it is the same.

Amir London
CEO, Kamada

When we started with the biosimilars, it goes back to 2019 when we signed the first agreement, the overall opinion, idea was that the price reduction will be maybe 30%. What we have seen over the last few years that it is almost like generics. It went down 60%, 70%. It started more with the European companies or even U.S. companies, Amgen, Sandoz, Alvotech, mAbxience. We are now looking east. It is much more depending now on the India-based company, Indian companies. Cost of goods is much lower. The pace they are moving is good, is fast. The recent agreement that we have signed have been with Indian companies.

That, I think, will be the main source for our additional new agreements over the next few years. Highly trusted supplier, very strong partnership and collaboration, moving fast, and better cost of goods compared to what we have seen from the European companies especially.

Annabel Samimy
Analyst, Stifel

I want to also talk about business development.

Amir London
CEO, Kamada

Correct.

Annabel Samimy
Analyst, Stifel

You are cash flow positive. You do have cash. You want to invest in your proprietary pipeline, in your proprietary products, in your expansion, and then do additional business development. How do you cover all the bases there, and what does a business development landscape look like?

Amir London
CEO, Kamada

Yeah. So we are looking to acquire assets which are commercial assets, either already launched in the market or pre-launch, but already after the regulatory approval. I do not think I mentioned it, but Kamada has changed significantly over the last few years. We have no binary events. I think the current risk profile of Kamada is low, and it is, I think, very safe to believe that we will be able to continue growing the business. I am telling some investor, "No, you will not wake up one morning and find that our stock went three times up, 300%, but you also will not wake up and find us at 50%." Okay? Because there are no binary events, no major clinical trials ahead of us.

We are focused on commercialization, profitability, business development, market access, geographical expansion, adding more and more products to our portfolio, which are synergetic, which fit our current or to-be-developed commercial footprint. We are looking at assets that are either in the transplantation field. We are currently covering all major transplant centers in America, so that the market that we feel very good about, we are becoming kind of a lead player in that market with the conferences and seminars and the KOLs. We are working with them, they know them, so that is a very safe area for us to bring more products. Secondly, we are looking at anything to do with plasma, of course. There are not many available products to buy. We are looking at distribution businesses, either in the U.S. or ex-U.S., and we are looking even to broader aspect of hospital-based products.

Could be a product that start in the hospital and then move to the community, but that is where we are focused on. We are doing our due diligence, and we hope to be able to transact on at least one asset over the next few months, because we have the bandwidth, we have the resources, the people to bring more product in, and I hope this will happen soon.

Annabel Samimy
Analyst, Stifel

Any expected need for cash to be able to do this business development, or you think you can-

Amir London
CEO, Kamada

The current-

Annabel Samimy
Analyst, Stifel

Sustain it yourself?

Amir London
CEO, Kamada

What we currently are looking at, we believe we can do it with our own resources. We have been very successful the last few quarters in investing in our commercialization growth and paying dividends. I think that the next step would be also to do an acquisition and to pay dividend in parallel to that. I hope we can do both. Just because we are generating cash, we generated $37 million over the last nine months.

Annabel Samimy
Analyst, Stifel

Nine months, yeah.

Amir London
CEO, Kamada

Okay. This allows us basically to build strong financial infrastructure that we have currently.

Annabel Samimy
Analyst, Stifel

Okay. Great. Well, that is all the time we have. Thank you very much.

Amir London
CEO, Kamada

Thank you.

Annabel Samimy
Analyst, Stifel

I appreciate the time.

Amir London
CEO, Kamada

Thanks. Yeah.